• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Gentian Diagnostics

Less than 1K followers

GENT

Oslo Børs

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus

Gentian Diagnostics is a medical diagnostics company that develops and manufactures in vitro diagnostic reagents for high-throughput analyzers. Gentian's expertise and focus lies in homogeneous immunoassays, specifically infections, inflammation, renal failure and congestive heart failure. The company's headquarters and production facilities are located in Moss, Norway, and serves the global human and veterinary diagnostics market through sales and representative offices in a number of key countries.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
20.10.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Regulatory press release09.07.2026 klo 08.30

Gentian Diagnostics - Second quarter 2026 report

Gentian Diagnostics
Regulatory press release02.07.2026 klo 14.18

Gentian Diagnostics: Invitation to presentation of second quarter results

Gentian Diagnostics
Regulatory press release24.06.2026 klo 09.30

GENT: ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT

Gentian Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release29.05.2026 klo 14.32

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release13.05.2026 klo 09.00

GENT: Meldepliktig handel og endring i styret

Gentian Diagnostics
Regulatory press release13.05.2026 klo 09.00

Flaggemelding - Gentian Diagnostics ASA

Gentian Diagnostics
Regulatory press release13.05.2026 klo 09.00

GENT: Board resignation

Gentian Diagnostics
Regulatory press release06.05.2026 klo 08.30

Gentian Diagnostics: First quarter 2026 report

Gentian Diagnostics
Regulatory press release06.05.2026 klo 08.30

GENT: Gentian Diagnostics ASA terminates NT-proBNP assay development

Gentian Diagnostics
Regulatory press release06.05.2026 klo 07.50

Gentian Diagnostics: Ex dividend NOK 0.60 today

Gentian Diagnostics
Regulatory press release05.05.2026 klo 12.57

Gentian Diagnostics: Minutes from Annual General Meeting

Gentian Diagnostics
Regulatory press release29.04.2026 klo 15.04

Gentian Diagnostics: Invitation to presentation of first quarter results

Gentian Diagnostics
Regulatory press release20.04.2026 klo 12.04

GENT: Gentian Diagnostics renews long-term faecal calprotectin partnership with Bühlmann Laboratories

Gentian Diagnostics
Regulatory press release13.04.2026 klo 14.20

Gentian Diagnostics: Notice of annual general meeting

Gentian Diagnostics
Regulatory press release10.04.2026 klo 11.02

Gentian Diagnostics ASA - Registration of share capital increase

Gentian Diagnostics
Regulatory press release20.03.2026 klo 09.36

Gentian Diagnostics: Annual report 2025

Gentian Diagnostics
Regulatory press release12.03.2026 klo 11.36

Gentian Diagnostics ASA - Mandatory notification of subscription of shares by primary insiders in Employee Share Purchase Program

Gentian Diagnostics
Regulatory press release12.03.2026 klo 11.36

Gentian Diagnostics ASA - Employee Share Purchase Program and share capital increase

Gentian Diagnostics
Regulatory press release19.02.2026 klo 11.21

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release13.02.2026 klo 10.26

GENT: Mandatory notification of trade

Gentian Diagnostics